Literature DB >> 34403803

Tezepelumab normalizes serum interleukin-5 and -13 levels in patients with severe, uncontrolled asthma.

Tuyet-Hang Pham1, Claudia Chen2, Gene Colice3, Jane R Parnes4, Janet M Griffiths5, Bill Cook6.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34403803     DOI： 10.1016/j.anai.2021.08.008

Source DB:  PubMed          Journal:  Ann Allergy Asthma Immunol        ISSN： 1081-1206            Impact factor:   6.347


× No keyword cloud information.
  3 in total

Review 1.  Role of thymic stromal lymphopoietin in allergy and beyond.

Authors:  Risa Ebina-Shibuya; Warren J Leonard
Journal:  Nat Rev Immunol       Date:  2022-06-01       Impact factor: 108.555

Review 2.  Targeting TSLP in Asthma.

Authors:  Jane R Parnes; Nestor A Molfino; Gene Colice; Ubaldo Martin; Jonathan Corren; Andrew Menzies-Gow
Journal:  J Asthma Allergy       Date:  2022-06-03

Review 3.  Dupilumab and tezepelumab in severe refractory asthma: new opportunities.

Authors:  Beatrice Ragnoli; Jaymin Morjaria; Patrizia Pignatti; Paolo Montuschi; Mariangela Barbieri; Lucrezia Mondini; Luca Ruggero; Liliana Trotta; Mario Malerba
Journal:  Ther Adv Chronic Dis       Date:  2022-05-25       Impact factor: 4.970
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.